ANAB

$46.991.55%-0.74

Dopo l'orario di chiusura: 47.73+0.74 +1.57%

Anaptysbio Inc (ANAB)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$47.73

Aprire:

$49.00

Volume 24 ore:

155,166

Volume relativo:

0.41

Capitalizzazione di mercato:

$1.40B

Reddito:

$232.39M

Utile/perdita netta:

-$26.79M

Rapporto P/E:

EPS:

-$1.08

Flusso di cassa netto:

$4.41M

1W Prestazione:

-6.95%

1M Prestazione:

-3.17%

6M Prestazione:

-32.66%

1Y Prestazione:

+35.26%

Intervallo 1D:

$45.81$49.00

Intervallo di 1 settimana:

$45.81$51.22

Portata 52W:

$30.27$73.30

Profilo aziendale di Anaptysbio Inc (ANAB)

Nome

Anaptysbio Inc

Settore

Healthcare

Industria

Biotechnology

Telefono

858-362-6295

Indirizzo

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, USA

Dipendente

104

@anaptysbio

Prossima data di guadagno

null

Ultimi documenti SEC

SEC

Discussioni di ANAB su X

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Anaptysbio Inc Azioni (ANAB) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-06-10	Resumed	H.C. Wainwright	Buy
2026-01-07	Resumed	UBS	Buy
2025-10-13	Iniziato	Barclays	Overweight
2025-06-04	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-02-04	Iniziato	Wolfe Research	Outperform
2024-12-11	Downgrade	H.C. Wainwright	Buy → Neutral
2024-12-02	Downgrade	BTIG Research	Buy → Neutral
2024-07-22	Iniziato	H.C. Wainwright	Buy
2024-07-19	Aggiornamento	JP Morgan	Neutral → Overweight
2024-04-16	Iniziato	Leerink Partners	Outperform
2024-04-11	Iniziato	Wells Fargo	Overweight
2024-03-12	Aggiornamento	Wedbush	Neutral → Outperform
2024-02-26	Iniziato	BTIG Research	Buy
2024-02-21	Iniziato	Stifel	Buy
2024-02-16	Iniziato	Piper Sandler	Overweight
2023-05-22	Aggiornamento	JP Morgan	Underweight → Neutral
2023-05-18	Iniziato	TD Cowen	Outperform
2023-01-06	Downgrade	Raymond James	Outperform → Mkt Perform
2022-11-01	Aggiornamento	Guggenheim	Neutral → Buy
2022-09-19	Resumed	H.C. Wainwright	Buy
2022-09-13	Downgrade	Truist	Buy → Hold
2022-09-01	Iniziato	Raymond James	Outperform
2022-03-22	Downgrade	Guggenheim	Buy → Neutral
2021-06-22	Iniziato	H.C. Wainwright	Buy
2021-05-21	Iniziato	UBS	Neutral
2021-03-16	Aggiornamento	Truist	Hold → Buy
2021-03-09	Downgrade	Wedbush	Outperform → Neutral
2021-03-08	Downgrade	JP Morgan	Overweight → Underweight
2021-02-11	Aggiornamento	JP Morgan	Underweight → Overweight
2020-10-27	Aggiornamento	Wedbush	Neutral → Outperform
2020-10-14	Aggiornamento	Guggenheim	Neutral → Buy
2019-11-08	Downgrade	JP Morgan	Overweight → Underweight
2019-11-08	Downgrade	Jefferies	Buy → Hold
2019-11-08	Downgrade	SunTrust	Buy → Hold
2019-11-08	Downgrade	Wedbush	Outperform → Neutral
2019-06-21	Downgrade	Credit Suisse	Outperform → Neutral
2019-06-21	Downgrade	Stifel	Buy → Hold
2018-12-20	Iniziato	H.C. Wainwright	Buy
2018-11-21	Iniziato	JP Morgan	Overweight
2018-07-19	Iniziato	Credit Suisse	Outperform
2018-04-04	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2018-03-27	Reiterato	Stifel	Buy
2018-03-06	Reiterato	Stifel	Buy
2018-02-15	Reiterato	SunTrust	Buy
2018-01-23	Reiterato	Credit Suisse	Outperform
2017-11-15	Iniziato	SunTrust	Buy
2017-11-09	Iniziato	Jefferies	Buy
2017-10-11	Reiterato	RBC Capital Mkts	Outperform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform

Anaptysbio Inc Azioni (ANAB) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	234.60	91.28	17.16	10.29	63.18
Research and development USD (M)	-	-	-	88.80	98.50
Operating expenses USD (M)	186.71	206.23	181.57	125.44	119.99
Operating income USD (M)	47.90	-114.95	-164.41	-115.15	-56.81
Income before tax USD (M)	-13.07	-145.23	-163.62	-128.70	-57.80
Income tax expense USD (M)	0.16	0.00	-0.00	0.02	0.00
Net income USD (M)	-13.23	-145.23	-163.62	-128.72	-57.80
Basic EPS USD/shares	-0.46	-5.12	-6.08	-4.57	-2.11
Diluted EPS USD/shares	-0.46	-5.12	-6.08	-4.57	-2.11
Basic weighted shares shares (M)	28.76	28.38	26.92	28.17	27.43
Diluted weighted shares shares (M)	28.76	28.38	26.92	28.17	27.43

Anaptysbio Inc Azioni (ANAB) insider trading

RENTON HOLLINGSOct 01 '26
Director
Transazione
Option Exercise
Costo
$18.03
#Azioni
5,000
Valore ($)
90,150
#Azioni Totale
15,995
RENTON HOLLINGSOct 01 '26
Director
Transazione
Sale
Costo
$49.87
#Azioni
5,000
Valore ($)
249,372
#Azioni Totale
10,995
HOLLINGS C RENTONOct 01 '26
Director
Transazione
Proposed Sale
Costo
$49.87
#Azioni
5,000
Valore ($)
249,372
#Azioni Totale
0
Orwin John ASep 15 '26
Director
Transazione
Option Exercise
Costo
$0.00
#Azioni
1,300
Valore ($)
0
#Azioni Totale
17,995
JOE ANTHONY WAREJul 13 '26
Director
Transazione
Proposed Sale
Costo
$67.17
#Azioni
10,694
Valore ($)
718,333
#Azioni Totale
0
JOE ANTHONY WAREJun 30 '26
Director
Transazione
Proposed Sale
Costo
$67.79
#Azioni
6,030
Valore ($)
408,774
#Azioni Totale
0
DENNIS MULROYJun 29 '26
Officer
Transazione
Proposed Sale
Costo
$63.45
#Azioni
9,476
Valore ($)
601,213
#Azioni Totale
0
DENNIS MULROYJun 26 '26
Officer
Transazione
Proposed Sale
Costo
$60.82
#Azioni
10,000
Valore ($)
608,183
#Azioni Totale
0
DENNIS MULROYJun 17 '26
Officer
Transazione
Proposed Sale
Costo
$60.00
#Azioni
850
Valore ($)
51,000
#Azioni Totale
0
DENNIS MULROYJun 16 '26
Officer
Transazione
Proposed Sale
Costo
$60.00
#Azioni
1,265
Valore ($)
75,900
#Azioni Totale
0

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
RENTON HOLLINGS	Director	Oct 01 '26	Option Exercise	$18.03	5,000	90,150	15,995
RENTON HOLLINGS	Director	Oct 01 '26	Sale	$49.87	5,000	249,372	10,995
HOLLINGS C RENTON	Director	Oct 01 '26	Proposed Sale	$49.87	5,000	249,372	0
Orwin John A	Director	Sep 15 '26	Option Exercise	$0.00	1,300	0	17,995
JOE ANTHONY WARE	Director	Jul 13 '26	Proposed Sale	$67.17	10,694	718,333	0
JOE ANTHONY WARE	Director	Jun 30 '26	Proposed Sale	$67.79	6,030	408,774	0
DENNIS MULROY	Officer	Jun 29 '26	Proposed Sale	$63.45	9,476	601,213	0
DENNIS MULROY	Officer	Jun 26 '26	Proposed Sale	$60.82	10,000	608,183	0
DENNIS MULROY	Officer	Jun 17 '26	Proposed Sale	$60.00	850	51,000	0
DENNIS MULROY	Officer	Jun 16 '26	Proposed Sale	$60.00	1,265	75,900	0

Anaptysbio Inc Borsa (ANAB) Ultime notizie

Oct 28, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth - Zacks Investment Research

Oct 28, 2026

Oct 27, 2026